Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedFeb 25, 2026
DataAggregated Company Financials
Companies318
  • 7D0.9%
  • 3M6.7%
  • 1Y25.0%
  • YTD6.6%

In the last week, the Pharma industry is flat overall, with Regencell Bioscience Holdings standing out by going down 18%. As for the the longer term, the industry is up 25% over the past 12 months. Looking forward, earnings are forecast to grow by 11% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 26 Feb 2026US$2.4tUS$411.7bUS$73.6b18.9x32.8x5.9x
Sat, 24 Jan 2026US$2.3tUS$404.7bUS$73.2b19.8x31.7x5.7x
Mon, 22 Dec 2025US$2.2tUS$402.8bUS$71.4b19.8x31.3x5.5x
Wed, 19 Nov 2025US$2.1tUS$402.7bUS$71.5b19.4x29.6x5.2x
Fri, 17 Oct 2025US$1.9tUS$389.2bUS$63.5b18x29.6x4.8x
Sun, 14 Sep 2025US$1.8tUS$387.9bUS$60.9b18.9x29.3x4.6x
Tue, 12 Aug 2025US$1.6tUS$387.9bUS$60.7b18.5x27x4.2x
Thu, 10 Jul 2025US$1.7tUS$382.7bUS$61.3b18.1x28.4x4.6x
Sat, 07 Jun 2025US$1.7tUS$382.7bUS$61.2b17.1x27.9x4.5x
Mon, 05 May 2025US$1.8tUS$382.7bUS$63.7b17.2x27.8x4.6x
Wed, 02 Apr 2025US$1.9tUS$380.6bUS$41.2b16.2x45.2x4.9x
Fri, 28 Feb 2025US$1.9tUS$381.0bUS$39.4b16.4x49.1x5.1x
Sun, 26 Jan 2025US$1.8tUS$370.4bUS$30.5b18.4x59.1x4.9x
Tue, 24 Dec 2024US$1.8tUS$369.4bUS$31.1b16.7x57.2x4.8x
Thu, 21 Nov 2024US$1.8tUS$373.8bUS$30.6b20.1x58.1x4.7x
Sat, 19 Oct 2024US$2.0tUS$365.3bUS$23.7b18.6x85.8x5.6x
Mon, 16 Sep 2024US$2.0tUS$364.3bUS$25.4b18.8x80.2x5.6x
Wed, 14 Aug 2024US$2.0tUS$362.1bUS$22.0b17.4x89x5.4x
Fri, 12 Jul 2024US$2.0tUS$357.6bUS$13.8b15.9x144.8x5.6x
Sun, 09 Jun 2024US$1.9tUS$358.3bUS$14.1b15.6x136.8x5.4x
Tue, 07 May 2024US$1.8tUS$358.0bUS$13.8b21.1x133.7x5.1x
Thu, 04 Apr 2024US$1.9tUS$355.2bUS$22.7b24.6x82.9x5.3x
Sat, 02 Mar 2024US$1.9tUS$355.3bUS$22.5b24.1x83.8x5.3x
Mon, 29 Jan 2024US$1.8tUS$375.2bUS$33.9b24.6x52.1x4.7x
Wed, 27 Dec 2023US$1.7tUS$375.2bUS$33.9b31.8x49.3x4.4x
Fri, 24 Nov 2023US$1.6tUS$375.1bUS$33.9b25.9x48.2x4.4x
Sun, 22 Oct 2023US$1.7tUS$382.7bUS$44.7b17.6x37x4.3x
Tue, 19 Sep 2023US$1.7tUS$381.8bUS$43.9b18.5x39.1x4.5x
Thu, 17 Aug 2023US$1.8tUS$381.7bUS$44.0b19.1x40.2x4.6x
Sat, 15 Jul 2023US$1.7tUS$392.8bUS$60.2b18.3x27.7x4.2x
Mon, 12 Jun 2023US$1.7tUS$393.0bUS$60.5b18.6x28.4x4.4x
Wed, 10 May 2023US$1.7tUS$395.1bUS$56.8b19.4x30.7x4.4x
Fri, 07 Apr 2023US$1.7tUS$401.2bUS$69.4b15.9x23.8x4.1x
Sun, 05 Mar 2023US$1.6tUS$401.2bUS$69.4b16.9x22.5x3.9x
Price to Earnings Ratio

22.5x


Total Market Cap: US$1.6tTotal Earnings: US$69.4bTotal Revenue: US$401.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 53.3x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 32.8x which is lower than its 3-year average PE of 53.3x.
  • The 3-year average PS ratio of 4.9x is lower than the industry's current PS ratio of 5.9x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.50%
Healthcare0.72%
Pharma0.86%
Pharma0.86%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$1.03k0.8%
+US$7.4b		12.4%PE44.5x
BMY Bristol-Myers SquibbUS$61.302.6%
+US$3.2b		6.8%PE17.7x
JAZZ Jazz PharmaceuticalsUS$196.8316.7%
+US$1.9b		36.5%PS2.8x
ELAN Elanco Animal HealthUS$26.848.3%
+US$1.0b		141.2%PS2.8x
MRK MerckUS$122.460.7%
+US$806.3m		37.0%PE16.6x

Latest News

MRK
US$122.46
Merck
7D
0.7%
1Y
37.0%
JAZZ
US$196.83
Jazz Pharmaceuticals
7D
16.7%
1Y
36.5%
CORT
US$36.22
Corcept Therapeutics
7D
-9.0%
1Y
-42.8%
JNJ
US$245.17
Johnson & Johnson
7D
0.07%
1Y
50.3%
PFE
US$27.09
Pfizer
7D
-1.0%
1Y
2.5%
HRMY
US$28.19
Harmony Biosciences Holdings
7D
-20.1%
1Y
-15.8%
AXSM
US$164.22
Axsome Therapeutics
7D
-11.1%
1Y
28.0%
ELAN
US$26.84
Elanco Animal Health
7D
8.3%
1Y
141.2%
BMY
US$61.30
Bristol-Myers Squibb
7D
2.6%
1Y
6.8%
LLY
US$1,028.83
Eli Lilly
7D
0.8%
1Y
12.4%

LLY: GLP-1 Obesity Leadership Will Drive Future Cardiometabolic And M&A Upside

Eli Lilly's analyst price targets have shifted higher, with our fair value estimate moving from $1,093.22 to $1,211.21, as analysts point to sustained GLP-1 obesity leadership, premium valuation support, and an expanding cardiometabolic pipeline as key drivers of their updated views. Analyst Commentary Recent Street research on Eli Lilly clusters around a few clear themes, with bullish analysts focusing on obesity leadership, cardiometabolic breadth, and M&A, while more cautious voices watch valuation and execution risk around the pipeline.
RGC
US$26.51
Regencell Bioscience Holdings
7D
-16.9%
1Y
20,458.8%

Regencell Bioscience Holdings Ltd. (RGC) The TCM Biotech Lottery Ticket: High Hopes and Extreme Volatility

If you're looking for a stock that perfectly embodies the wild, speculative side of the market for your viewers, Regencell Bioscience (RGC) is it. As of late February 2026, this Hong Kong-headquartered, early-stage bioscience company is trading around $29.17 , following a period of mind-bending volatility where the stock surged thousands of percent over the past year.
TEVA
US$33.62
Teva Pharmaceutical Industries
7D
-1.4%
1Y
100.4%

TEVA: Affordable Medicines And 2026 R&D Progress Will Shape Medium Term Outlook

Narrative Update Overview The analyst price target for Teva Pharmaceutical Industries has been revised modestly higher to $37.95, with analysts pointing to updated fair value estimates, slightly adjusted discount rates, a new revenue growth outlook, and recent Street research highlighting potential pipeline catalysts and the appeal of affordable medicines heading into 2026. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries has centered on refreshed price targets, the potential of the R&D pipeline heading into 2026, and the appeal of the affordable medicines theme.
OCUL
US$9.50
Ocular Therapeutix
7D
38.1%
1Y
36.9%

OCUL: Potential Higher Sanofi Bid Will Drive Bullish Repricing

Analysts have adjusted their price target on Ocular Therapeutix to $20.00 from $19.00, reflecting updated assumptions around revenue growth, profit margins, discount rate and future P/E that they view as more closely aligned with the company’s current outlook. What's in the News Sanofi is reported to be preparing a higher bid for Ocular Therapeutix, signaling continuing interest in the company as a potential acquisition target (IBD, Periodicals).
MANE
US$42.17
Veradermics
7D
-15.8%
1Y
n/a
BLTE
US$188.04
Belite Bio
7D
8.1%
1Y
238.8%
LQDA
US$30.00
Liquidia
7D
-14.2%
1Y
93.8%